VivoSeq
Musculoskeletal

Fibromyalgia

129

Pipeline Programs

33

Active Trials

55

Companies Involved

Fibromyalgia is a highly competitive landscape with 129 programs across 55 companies. The most active players are Lykos Therapeutics, Astellas, Boehringer Ingelheim. 32 therapies are approved with 24 more in late-stage development.

Pipeline Metrics

Competitive Density

75/100

Pipeline Velocity

47/100

Mech. Concentration

12/100

Completion Rate

84/100

Attrition Rate

12/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

96%

Small molecule

145 of 151 classified programs — the dominant modality here.

4%ALL OTHERSMonoclonal antibody43%Vaccine21%

Small molecule leads; the ring shows all 151 classified programs, each share of the total. Modality classified for 99% of 153 pipeline programs.

Trial Status

237

clinical trials

Completed154 · 65%
Recruiting24 · 10%
Terminated21 · 9%
Unknown status21 · 9%
Withdrawn8 · 3%
Not yet recruiting5 · 2%
Other4 · 2%

Trial Activity

237 trials

The Impact of THC on Pain Modulation in Fibromyalgia
Recruiting··N/A·NCT05644054·40 enrolled
Nitrous Oxide as Treatment for Fibromyalgia
Recruiting·UUniversity of Chicago·Phase 2·NCT05357066·50 enrolled
Metformin for Fibromyalgia Symptoms (INFORM Trial)
Recruiting·UUniversity of Utah·Phase 2·NCT05900466·72 enrolled
Silymarin vs Hesperidin/Diosmin in Fibromyalgia
Recruiting··N/A·NCT07293767·90 enrolled
Duloxetine Metabolism and Fibromyalgia
Recruiting·UUniversity of Utah·N/A·NCT06866444·100 enrolled
Page 1 of 16

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)